These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20220376)

  • 1. Prolonged medically recorded treatment interruptions among HIV-infected patients on highly active antiretroviral therapy with controlled viremia: when physicians have to juggle patient negotiation and guidelines.
    Protopopescu C; Roux P; Carrieri MP; Katlama C; Collin F; Besnier JM; Chêne G; Raffi F; Spire B; Leport C;
    J Acquir Immune Defic Syndr; 2010 Apr; 53(4):544-6. PubMed ID: 20220376
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G; Girardi E; Cozzi-Lepri A; Capobianchi MR; De Luca A; Puoti M; Petrelli E; Carnevale G; Rizzardini G; Grossi PA; Viganò P; Moioli MC; Carletti F; Solmone M; Ippolito G; Monforte AD; ;
    Clin Infect Dis; 2005 Jun; 40(12):e101-9. PubMed ID: 15909251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Duration of Viral Suppression and Risk of Rebound Viremia with First-Line Antiretroviral Therapy in Rural Uganda.
    Musinguzi N; Mocello RA; Boum Y; Hunt PW; Martin JN; Haberer JE; Bangsberg DR; Siedner MJ
    AIDS Behav; 2017 Jun; 21(6):1735-1740. PubMed ID: 27256394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Structured therapeutic interruption in patients infected with HIV-1 experiencing a block in their antiretroviral treatment: preliminary results].
    Rey D; Schmitt MP; Hess-Kempf G; Krantz V; Partisani M; Bernard-Henry C; Lang JM
    Pathol Biol (Paris); 2001 Sep; 49(7):559-66. PubMed ID: 11642019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Which adherence measure - self-report, clinician recorded or pharmacy refill - is best able to predict detectable viral load in a public ART programme without routine plasma viral load monitoring?
    Mekuria LA; Prins JM; Yalew AW; Sprangers MA; Nieuwkerk PT
    Trop Med Int Health; 2016 Jul; 21(7):856-69. PubMed ID: 27118068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunovirological outcomes and resistance patterns at 4 years of antiretroviral therapy use in HIV-infected patients in Cambodia.
    Pujades-Rodríguez M; Schramm B; Som L; Nerrienet E; Narom P; Chanchhaya N; Ferradini L; Balkan S
    Trop Med Int Health; 2011 Feb; 16(2):205-13. PubMed ID: 21087376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structured treatment interruptions in HIV/AIDS therapy.
    Lisziewicz J; Lori F
    Microbes Infect; 2002 Feb; 4(2):207-14. PubMed ID: 11880054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
    Panel de expertos de Gesida y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone.
    Hoffmann CJ; Maritz J; van Zyl GU
    Trop Med Int Health; 2016 Feb; 21(2):219-23. PubMed ID: 26584666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients.
    Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V;
    J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of cessation of highly active antiretroviral therapy during a discordant response: implications for scheduled therapeutic interruptions.
    Hawley-Foss N; Mbisa G; Lum JJ; Pilon AA; Angel JB; Garber G; Badley AD
    Clin Infect Dis; 2001 Aug; 33(3):344-8. PubMed ID: 11438900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An evaluation of antiretroviral HIV/AIDS treatment in a Rio de Janeiro public clinic.
    Carmody ER; Diaz T; Starling P; dos Santos AP; Sacks HS
    Trop Med Int Health; 2003 May; 8(5):378-85. PubMed ID: 12753630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological changes during treatment interruptions: risk factors and clinical sequelae.
    Poulton MB; Sabin CA; Fisher M
    AIDS; 2003 Jan; 17(1):126-8. PubMed ID: 12478080
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunologic and virologic responses to antiretroviral therapy in treatment-naïve, HIV-infected elderly patients.
    Ocheretyaner ER; Yusuff J; Park TE
    Int J STD AIDS; 2019 Nov; 30(13):1304-1310. PubMed ID: 31726933
    [No Abstract]   [Full Text] [Related]  

  • 15. Predicting short-term interruptions of antiretroviral therapy from summary adherence data: Development and test of a probability model.
    Harris RA; Haberer JE; Musinguzi N; Chang KM; Schechter CB; Doubeni CA; Gross R
    PLoS One; 2018; 13(3):e0194713. PubMed ID: 29566096
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunovirologic consequences and safety of short, non-structured interruptions of successful antiretroviral treatment.
    Sanchez R; Portilla J; Gimeno A; Boix V; Llopis C; Sanchez-Paya J; Merino E; de la Sen ML; Muñoz C; Reus S; Plazas J
    J Infect; 2007 Feb; 54(2):159-66. PubMed ID: 16690132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of intermittent viremia during highly active antiretroviral therapy in patients who initiate therapy during chronic versus acute and early human immunodeficiency virus type 1 infection.
    Di Mascio M; Markowitz M; Louie M; Hurley A; Hogan C; Simon V; Follmann D; Ho DD; Perelson AS
    J Virol; 2004 Oct; 78(19):10566-73. PubMed ID: 15367623
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rational use of antiretroviral therapy in low-income and middle-income countries: optimizing regimen sequencing and switching.
    Elliott JH; Lynen L; Calmy A; De Luca A; Shafer RW; Zolfo M; Clotet B; Huffam S; Boucher CA; Cooper DA; Schapiro JM
    AIDS; 2008 Oct; 22(16):2053-67. PubMed ID: 18753937
    [No Abstract]   [Full Text] [Related]  

  • 20. [Viral load and CD4+ lymphocyte count in the era of highly active antiretroviral therapy].
    Martín JC; Fernández P; Soriano V; Martínez P; González-Lahoz J
    Med Clin (Barc); 2000 Jun; 115(3):118. PubMed ID: 10965488
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.